Effectiveness and Safety of SGLT2 Inhibitor Treatment on Renal Outcomes in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study in South Korea

被引：0
|
作者：
Chang, Junhyuk [1 ]
Kim, Chungsoo [1 ]
Choi, Heejung [2 ]
Park, Rae Woong [1 ]
Lee, Sukhyang [3 ]
机构：
[1] Ajou Univ, Dept Biomed Sci, Grad Sch Med, Suwon, South Korea
[2] Ajou Univ, Dept Nephrol, Sch Med, Suwon, South Korea
[3] Ajou Univ, Div Clin Pharm, Coll Pharm, Suwon, South Korea
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1151
引用
收藏
页码：516 / 516
页数：1
相关论文
共 50 条
  • [31] Is an SGLT2 inhibitor right for your patient with type 2 diabetes?
    Lisenby, Katelin M.
    Meyer, Allison
    Slater, Nicole A.
    JOURNAL OF FAMILY PRACTICE, 2016, 65 (09): : 587 - 593
  • [32] Insulin Independence With SGLT2 Inhibitor Use in Type 2 Diabetes
    Jack, Gwendolyne Anyanate
    Kashyap, Sangeeta R.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2023, 108 (10): : E1153 - E1154
  • [33] Ketoacidosis in Type 2 Diabetes with and without SGLT2 Inhibitor Therapy
    Koerbel, Theresa
    Zitterl, A.
    Jagoutz, T.
    Peric, S.
    Stulnig, T. M.
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S765 - S765
  • [34] Effects of 5 weeks of treatment with dapagliflozin, a SGLT2 inhibitor, on energy metabolism in patients with type 2 diabetes
    Op den Kamp, Y.
    de Ligt, M.
    Dautzenberg, B. D.
    Esterline, R.
    Hoeks, J.
    Schrauwen-Hinderling, V. B.
    Havekes, B.
    Oscarsson, J.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S115 - S115
  • [35] Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
    Kaushal, Shaveta
    Singh, Harmanjit
    Thangaraju, Pugazhenthan
    Singh, Jasbir
    NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES, 2014, 6 (03) : 107 - 113
  • [36] SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?
    Saisho, Yoshifumi
    DISEASES, 2020, 8 (02)
  • [37] Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Tofogliflozin (A SELECTIVE SGLT2 Inhibitor) in Patients with Type 2 Diabetes Mellitus
    Ikeda, Sachiya
    Takano, Yasuki
    Schwab, Dietmar
    Portron, Agnes
    Kasahara-Ito, Nahoko
    Saito, Tomohisa
    Iida, Satofumi
    DRUG RESEARCH, 2019, 69 (06) : 314 - 322
  • [38] Cardiovascular outcomes with SGLT2 inhibitors in patients with atrial fibrillation and type 2 diabetes
    Kim, S.
    Cho, Y.
    Suh, Y.
    Seo, D.
    Kim, Y.
    Shin, S-H
    DIABETOLOGIA, 2024, 67 : S342 - S342
  • [39] Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus
    Singh, Mahakpreet
    Sharma, Ruchika
    Kumar, Anoop
    CURRENT DRUG SAFETY, 2019, 14 (02) : 87 - 93
  • [40] Clinical Profile and Treatment Adherence in Patients with Type 2 Diabetes and Chronic Kidney Disease Who Initiate an SGLT2 Inhibitor: A Multi-cohort Study
    Johannes, Catherine B.
    Ziemiecki, Ryan
    Pladevall-Vila, Manel
    Ebert, Natalie
    Kovesdy, Csaba P.
    Thomsen, Reimar W.
    Baak, Brenda N.
    Garcia-Sempere, Anibal
    Kanegae, Hiroshi
    Coleman, Craig I.
    Walsh, Michael
    Andersen, Ina Trolle
    Bernal, Clara Rodriguez
    Cabaninas, Celia Robles
    Christiansen, Christian Fynbo
    Farjat, Alfredo E.
    Gay, Alain
    Gee, Patrick
    Herings, Ron M. C.
    Hurtado, Isabel
    Kashihara, Naoki
    Kristensen, Frederik Pagh Bredahl
    Liu, Fangfang
    Okami, Suguru
    Overbeek, Jetty A.
    Penning-van Beest, Fernie J. A.
    Yamashita, Satoshi
    Yano, Yuichiro
    Layton, J. Bradley
    Vizcaya, David
    Oberprieler, Nikolaus G.
    DIABETES THERAPY, 2025, 16 (02) : 205 - 226
12345